The Revolutionary Impact of Dostarlimab in Treating dMMR/MSI-H Rectal Cancer: A Comprehensive Review
Keywords:
Dostarlimab, PD-1 Inhibitor, dMMR/MSI-H, Rectal Cancer, Clinical Trials, FDA Approval, Oncology, Cancer Treatment.Abstract
This article reviews the groundbreaking results of Dostarlimab, a PD-1 inhibitor, in the treatment of dMMR/MSI-H rectal cancer, a rare and difficult-to-treat subtype of colorectal cancer. Dostarlimab has demonstrated unprecedented efficacy, achieving a 100% clinical response rate in patients undergoing treatment, with no recurrence or metastasis observed. These promising results were observed in a pivotal clinical trial where patients who were previously facing limited treatment options showed complete remission after receiving Dostarlimab as a monotherapy. The article delves into the mechanisms of action of Dostarlimab, its role in immunotherapy, and its potential as a future standard of care for dMMR/MSI-H rectal cancer. Additionally, the article explores the ongoing clinical trials and FDA approval, highlighting the significant hope this treatment brings to patients and oncologists alike. The potential long-term impacts of Dostarlimab on the oncology landscape are also discussed, focusing on its ability to revolutionize cancer treatment paradigms.
References
Cercek, A., Lumish, M., Sinopoli, J., Weiss, J., Shia, J., Lamendola-Essel, M., El Dika, I. H., Segal, N., Shcherba, M., Sugarman, R., Stadler, Z., Yaeger, R., Smith, J. J., Rousseau, B., Argiles, G., Patel, M., Desai, A., Saltz, L. B., Widmar, M., … Diaz, L. A. (2022). PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer. New England Journal of Medicine, 386(25), 2363–2376. https://doi.org/10.1056/nejmoa2201445
T cell. T Cell - an overview | ScienceDirect Topics. (n.d.). https://www.sciencedirect.com/topics/immunology-and-microbiology/t-cell
Babar, Q., Saeed, A., Murugappan, S., Dhumal, D., Tabish, T., & Thorat, N. D. (2023). Promise of dostarlimab in cancer therapy: Advancements and cross-talk considerations. Drug Discovery Today, 28(6), 103577. https://doi.org/10.1016/j.drudis.2023.103577
Dockrill, P. (2022, June 6). Every single patient in this small experimental drug trial saw their cancer disappear. ScienceAlert. https://www.sciencealert.com/every-single-patient-in-this-small-experimental-drug-trial-saw-their-cancer-disappear
Downloads
Published
Versions
- 2025-01-10 (2)
- 2025-01-10 (1)
